You are being forwarded to your requested URL of https://www.finnegan.com/en/insights/blogs/ip-fda-blog/cafc-applies-collateral-estoppel-sua-sponte-in-xy-v.-trans-ova-genetics.html?utm_source=mondaq&utm_medium=syndication&utm_content=sourceoriginal&utm_campaign=